Related references
Note: Only part of the references are listed.Novel Coumarin Derivatives Containing a Triazole Moiety: A Study on Synthesis, Cytotoxicity, Membrane Dysfunction, Apoptosis, Cell Cycle, and Antiangiogenic Effects
Adem Guner et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2022)
Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer
Quanyu Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Yi Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Herve Tilly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system
Chang Hoon Ji et al.
NATURE COMMUNICATIONS (2022)
Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu et al.
CHEMBIOCHEM (2022)
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
Fan Shi et al.
DRUG DELIVERY (2022)
Hybrid molecule between platanic acid and LCL-161 as a yes-associated protein degrader
Naoko Nakano et al.
JOURNAL OF BIOCHEMISTRY (2022)
Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
Guliang Yang et al.
FOOD SCIENCE AND HUMAN WELLNESS (2022)
Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay
Hye Yun Chae et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Radiosensitization of human pancreatic cancer by piperlongumine analogues
Hao Ma et al.
CHINESE CHEMICAL LETTERS (2021)
Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6
Zhuoxian Cao et al.
ACS CHEMICAL BIOLOGY (2021)
Development of a LC–MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study
Catherine Gowland et al.
Bioanalysis (2021)
Natural products in drug discovery: advances and opportunities
Atanas G. Atanasov et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
Yingying Xu et al.
GASTRIC CANCER (2021)
Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?
Marta Szumilak et al.
MOLECULES (2021)
HER2-targeted therapies in gastric cancer
Yinxing Zhu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein
Zhiwen Qi et al.
BIOORGANIC CHEMISTRY (2021)
Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer
Yuhao Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer
Huan Long et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Wen Shuai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Natural Product-Based Hybrids as Potential Candidates for the Treatment of Cancer: Focus on Curcumin and Resveratrol
Nicola Micale et al.
MOLECULES (2021)
Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
Do-Hun Kim et al.
BIOMATERIALS RESEARCH (2021)
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng et al.
CLINICAL CANCER RESEARCH (2021)
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Design, synthesis and biological evaluation of phenol-linked uncialamycin antibody-drug conjugates
Yam B. Poudel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Molecular hybrid design, synthesis, in vitro and in vivo anticancer evaluation, and mechanism of action of N-acylhydrazone linked, heterobivalent β-carbolines
Liang Guo et al.
BIOORGANIC CHEMISTRY (2020)
ROS in cancer therapy: the bright side of the moon
Bruno Perillo et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3
Rizhen Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer
Jiaxuan He et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Toxicity and Antitumor Activity of a Thiophene-Acridine Hybrid
Thais Lisboa et al.
MOLECULES (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Current scenario of indole derivatives with potential anti-drug-resistant cancer activity
Yanshu Jia et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
A review of traditional uses, phytochemistry and pharmacology of the genus Indigofera
Elise Gerometta et al.
JOURNAL OF ETHNOPHARMACOLOGY (2020)
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
Gavin Bennett et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Exploiting the folate receptor α in oncology
Mariana Scaranti et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
Bingqi Tong et al.
ACS CHEMICAL BIOLOGY (2020)
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
F. Montemurro et al.
ANNALS OF ONCOLOGY (2020)
CT1-3, a novel magnolol-sulforaphane hybrid suppresses tumorigenesis through inducing mitochondria-mediated apoptosis and inhibiting epithelial mesenchymal transition
Cheng Tao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Formulation of More Efficacious Curcumin Delivery Systems Using Colloid Science: Enhanced Solubility, Stability, and Bioavailability
Bingjing Zheng et al.
MOLECULES (2020)
Drug Delivery Systems of Natural Products in Oncology
Marisa Colone et al.
MOLECULES (2020)
Antibody-Drug Conjugates for Cancer Therapy
Umbreen Hafeez et al.
MOLECULES (2020)
Bardoxolone conjugation enables targeted protein degradation of BRD4
Bingqi Tong et al.
SCIENTIFIC REPORTS (2020)
Navigating the Synthesis of Quinoline Hybrid Molecules as Promising Anticancer Agents
Pravati Panda et al.
CHEMISTRYSELECT (2020)
Targeted degradation of CD147 proteins in melanoma
Zhe Zhou et al.
BIOORGANIC CHEMISTRY (2020)
Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
Hwa Yeon Jeong et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Comprehensive review on current developments of quinoline-based anticancer agents
Shweta Jain et al.
ARABIAN JOURNAL OF CHEMISTRY (2019)
Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs
Michael D. Shultz
JOURNAL OF MEDICINAL CHEMISTRY (2019)
An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent
Wang Yan et al.
INVESTIGATIONAL NEW DRUGS (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells
Jian-Ning Yao et al.
INVESTIGATIONAL NEW DRUGS (2019)
Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells
Benardina Ndreshkjana et al.
CELL DEATH & DISEASE (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Jessica N. Spradlin et al.
NATURE CHEMICAL BIOLOGY (2019)
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
Devalingam Mahalingam et al.
CANCERS (2019)
Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids
Harbinder Singh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Coumarin-containing hybrids and their anticancer activities
Longfei Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Kerry A. Whalen et al.
MOLECULAR CANCER THERAPEUTICS (2019)
The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia
Stephen A. Strickland et al.
BLOOD (2019)
Indole: A privileged scaffold for the design of anti-cancer agents
Yichao Wan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Synthesis and bioevaluation of novel steroidal isatin conjugates derived from epiandrosterone/androsterone
Shaoyong Ke et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Oxidation resistance 1 is a novel senolytic target
Xin Zhang et al.
AGING CELL (2018)
Design and Synthesis of DNA-Interactive -Carboline-Oxindole Hybrids as Cytotoxic and Apoptosis-Inducing Agents
Ramya Tokala et al.
CHEMMEDCHEM (2018)
Success stories of natural product-based hybrid molecules for multi factorial diseases
Shalki Choudhary et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors
Manda Sathish et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
beta-Carboline derivatives as novel antivirals for herpes simplex virus
M. Micaela Gonzalez et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer
Bethany Powell Gray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Conjugates of 17-substituted testosterone and epitestosterone with pyropheophorbide a differing in the length of linkers
Vladimir A. Zolottsev et al.
STEROIDS (2018)
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic
Joseph A. Reddy et al.
SCIENTIFIC REPORTS (2018)
Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity
Jinlei Bian et al.
BIOORGANIC CHEMISTRY (2018)
Artemisinin-Daumone Hybrid Inhibits Cancer Cell-Mediated Osteolysis by Targeting Cancer Cells and Osteoclasts
Gwang Taek Ma et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Cancer-targeted delivery systems based on peptides
Theodora Chatzisideri et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Evaluating intrinsic and non-intrinsic cancer risk factors
Song Wu et al.
NATURE COMMUNICATIONS (2018)
Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-I-induced resistance
Kamontip Chaikomon et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Aptamers as targeted therapeutics: current potential and challenges
Jiehua Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Physical and Chemical Stability of Curcumin in Aqueous Solutions and Emulsions: Impact of pH, Temperature, and Molecular Environment
Mahesh Kharat et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2017)
Food macromolecule based nanodelivery systems for enhancing the bioavailability of polyphenols
Bing Hu et al.
JOURNAL OF FOOD AND DRUG ANALYSIS (2017)
Approach to ferrocenyl-podophyllotoxin analogs and their evaluation as anti-tumor agents
Matthieu Beauperin et al.
JOURNAL OF ORGANOMETALLIC CHEMISTRY (2017)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2017)
Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors
Ryan C. Chai et al.
MOLECULAR ONCOLOGY (2017)
Antibodies and associates: Partners in targeted drug delivery
Patrick J. Kennedy et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Ruthenium(II)/triphenylphosphine complexes: An effective way to improve the cytotoxicity Of lapachol
Katia M. Oliveira et al.
POLYHEDRON (2017)
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
LANCET HAEMATOLOGY (2017)
Cancer combination therapies with artemisinin-type drugs
Thomas Efferth
BIOCHEMICAL PHARMACOLOGY (2017)
Chalcone: A Privileged Structure in Medicinal Chemistry
Chunlin Zhuang et al.
CHEMICAL REVIEWS (2017)
Cleaning House: Selective Autophagy of Organelles
Allyson L. Anding et al.
DEVELOPMENTAL CELL (2017)
Peptide-drug conjugates as effective prodrug strategies for targeted delivery
Yin Wang et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
D. Mahalingam et al.
BRITISH JOURNAL OF CANCER (2016)
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer
Hanlin Zeng et al.
CANCER CELL (2016)
An overview of molecular hybrids in drug discovery
Gervais Berube
EXPERT OPINION ON DRUG DISCOVERY (2016)
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Paul E. Hughes et al.
TRENDS IN IMMUNOLOGY (2016)
Chalcone-Induced Apoptosis through Caspase-Dependent Intrinsic Pathways in Human Hepatocellular Carcinoma Cells
Rodrigo Ramirez-Tagle et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents
Shaoyong Ke et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Imran Ali et al.
CURRENT DRUG TARGETS (2015)
The re-emergence of natural products for drug discovery in the genomics era
Alan L. Harvey et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Autophagy at the crossroads of catabolism and anabolism
Jasvinder Kaur et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease
Madhuri Venigalla et al.
NEURAL REGENERATION RESEARCH (2015)
Formononetin inhibits enterovirus 71 replication by regulating COX-2/PGE2 expression
Huiqiang Wang et al.
VIROLOGY JOURNAL (2015)
Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anticancer agents
Narsimha Reddy Penthala et al.
MEDCHEMCOMM (2015)
Formononetin promotes angiogenesis through the estrogen receptor alpha-enhanced ROCK pathway
Shang Li et al.
SCIENTIFIC REPORTS (2015)
Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance
Daniel J. O'Shannessy et al.
Oncotarget (2015)
Anticancer effect of antimalarial artemisinin compounds
A. K. Das
ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH (2015)
Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents
Daniel Yuan Qiang Wong et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Acridine and its derivatives: a patent review (2009-2013)
Bin Zhang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Targeting the Androgen Receptor with Steroid Conjugates
Paul M. Levine et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Artemisinins: Pharmacological actions beyond anti-malarial
Wanxing Eugene Ho et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
Maria P. Crespo-Ortiz et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
Steroid hormone receptors in cancer development A target for cancer therapeutics
Nihal Ahmad et al.
CANCER LETTERS (2011)
Discovery of Artemisinin-Glycolipid Hybrids as Anti-oral Cancer Agents
Jeremy Ricci et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2011)
Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers
Ahmed Kamal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Honokiol and Magnolol as Multifunctional Antioxidative Molecules for Dermatologic Disorders
Jui-Lung Shen et al.
MOLECULES (2010)
Development and application of Hsp90 inhibitors
David B. Solit et al.
DRUG DISCOVERY TODAY (2008)
Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters
Elena A. Dubikovskaya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder
S Abraham et al.
CLINICAL CANCER RESEARCH (2006)
Tumor selectivity of Hsp90 inhibitors: The explanation remains elusive
Gabriela Chiosis et al.
ACS CHEMICAL BIOLOGY (2006)
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
N Parker et al.
ANALYTICAL BIOCHEMISTRY (2005)
Cancer stem cells: lessons from leukemia
JCY Wang et al.
TRENDS IN CELL BIOLOGY (2005)
Histone, deacetylase inhibitor trichostatin a induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells
Y Yamashita et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Share Paper
